Schicktanz Nathalie, Gerhards Christiane, Schlitt Thomas, Aerni Amanda, Müggler Elia, de Quervain Dominique, Papassotiropoulos Andreas, Boonen Georg, Drewe Juergen, Butterweck Veronika
Division of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland.
Research Cluster Molecular and Cognitive Neurosciences, Department of Biomedicine, University of Basel, Basel, Switzerland.
Brain Behav. 2025 Jun;15(6):e70600. doi: 10.1002/brb3.70600.
OBJECTIVE/BACKGROUND: This study evaluated the feasibility of investigating the effect of a valerian and hops-based herbal medication (Ze 91019) on daytime cognitive performance, psychological parameters, and sleep measures in individuals with occasional sleep problems.
A randomized, double-blind, placebo-controlled study was conducted in 40 participants over a 21-day run-in period and a 21-day treatment period. Participants used Fitbit sleep trackers and completed daily online cognitive tests (i.e., reaction time and working memory), and surveys to assess subjective psychological outcomes (i.e., cognitive performance, stress levels, tiredness, mood, quality of life, and motivation).
The study design proved feasible, with high adherence to the study protocol. Exploratory analyses revealed a statistically significant increase in sleep duration during the treatment period for participants using Ze 91019 compared to placebo (mean daily increase: 21.7 min, p = 0.019) without statistically significant effects on cognitive or psychological outcomes. Moreover, Ze 91019 statistically significantly increased the sleep duration of the shortest night in the treatment period by 48.7 minutes. The medication was well-tolerated.
The study design proved feasible, and Ze 91019 increased sleep duration without affecting daytime cognitive or psychological outcomes.
The trial has been preregistered at www.
gov (NCT05684523).
目的/背景:本研究评估了一种基于缬草和啤酒花的草药药物(Ze 91019)对偶尔有睡眠问题的个体白天认知表现、心理参数和睡眠指标的影响的可行性。
在40名参与者中进行了一项随机、双盲、安慰剂对照研究,包括21天的导入期和21天的治疗期。参与者使用Fitbit睡眠追踪器,完成每日在线认知测试(即反应时间和工作记忆),并通过调查评估主观心理结果(即认知表现、压力水平、疲劳、情绪、生活质量和动机)。
研究设计证明是可行的,参与者对研究方案的依从性很高。探索性分析显示,与安慰剂相比,使用Ze 91019的参与者在治疗期间的睡眠时间有统计学意义的增加(平均每日增加:21.7分钟,p = 0.019),而对认知或心理结果没有统计学意义的影响。此外,Ze 91019在治疗期间使最短夜间睡眠时间在统计学上显著增加了48.7分钟。该药物耐受性良好。
研究设计证明是可行的,Ze 91019增加了睡眠时间,而不影响白天的认知或心理结果。